A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer
Status:
Completed
Trial end date:
2019-09-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if MEDI4736 will be adequately tolerated in
combination with tremelimumab in subjects with advanced non-small cell lung cancer (NSCLC).